Biovail To Pay $24.6M Over Cardizem Marketing

Law360, New York (May 16, 2008, 12:00 AM EDT) -- Biovail Corp.’s pharmaceutical subsidiary has agreed to shell out $24.6 million to resolve criminal charges brought by the U.S. Department of Justice related to Biovail's blood pressure drug Cardizem LA.

The Toronto-based firm said Friday its New Jersey unit, Biovail Pharmaceuticals Inc., will also plead guilty to charges that it paid people to induce them to purchase or prescribe the medication.

Biovail, which is Canada’s biggest publicly traded pharmaceutical firm, said the agreement releases it from any criminal liability and allows the company to continue to...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.